3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
1
Status
Recruiting
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Gastrointestinal
1
Conditions
Carcinoma, Non-Small-Cell Lung
18
Neoplasm Metastasis
8
Esophageal Neoplasms
8
Carcinoma, Hepatocellular
7
Melanoma
6
Lung Neoplasms
6
Squamous Cell Carcinoma of Head and Neck
5
Neoplasms
5
Breast Neoplasms
5
Stomach Neoplasms
4
Colorectal Neoplasms
3
Uterine Cervical Neoplasms
2
Small Cell Lung Carcinoma
2
Recurrence
2
Rectal Neoplasms
2
Pathologic Complete Response
2
Nasopharyngeal Carcinoma
2
Head and Neck Neoplasms
2
Gastrointestinal Neoplasms
2
Carcinoma, Renal Cell
2
Carcinoma
2
Breast Neoplasms, Male
2
Turcot syndrome
1
Triple Negative Breast Neoplasms
1
Solid Tumor Cancer
1
Small Cell Lung Cancer Extensive Stage
1
Sarcoma
1
Radiation Injuries
1
Prostatic Neoplasms
1
Pleural Mesothelial Neoplasm
1
Interventions
Cisplatin
26
Paclitaxel
21
pembrolizumab
15
Radiotherapy
13
Carboplatin
13
tislelizumab
12
Fluorouracil
12
Drug Therapy
11
Irinotecan
9
toripalimab
8
Esophagectomy
8
Oxaliplatin
6
Nivolumab
6
Capecitabine
6
Neoadjuvant Therapy
5
Leucovorin
5
Docetaxel
5
lenvatinib
4
camrelizumab
4
Taxes
4
Radiation
4
Levoleucovorin
4
Immune Checkpoint Inhibitors
4
Albumin-Bound Paclitaxel
4
130-nm albumin-bound paclitaxel
4
spartalizumab
3
sintilimab
3
apatinib
3
Itraconazole
3
Injections
3
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Esophageal Squamous Cell Carcinoma
×
Immunotherapy
×
1 year
×
Clear all
NCT05978193
2026-01-22
SCR-ESCC-01
Shanghai Chest Hospital
Phase 2
Recruiting
100 enrolled